Home Cart Sign in  
Chemical Structure| 2244904-70-7 Chemical Structure| 2244904-70-7

Structure of BAY-293
CAS No.: 2244904-70-7

Chemical Structure| 2244904-70-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BAY-293 selectively inhibits the KRAS-SOS1 interaction with an IC50 of 21nM.

Synonyms: BAY-293

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BAY-293

CAS No. :2244904-70-7
Formula : C25H28N4O2S
M.W : 448.58
SMILES Code : N(C1=NC(=NC2C=C(C(=CC=21)OC)OC)C)[C@@H](C1SC=C(C2C=CC=CC=2CNC)C=1)C
Synonyms :
BAY-293
MDL No. :MFCD31813755
InChI Key :WEGLOYDTDILXDA-OAHLLOKOSA-N
Pubchem ID :137322663

Safety of BAY-293

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of BAY-293

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
TE671 cells 0.2 µM BAY-293 significantly reduced MYC expression in TE671 cells. PMC11754616
BH828 1.7 µM 4 days Test the cytotoxicity of BAY-293 against NSCLC and PDAC cell lines PMC8488304
BH837 3.7 µM 4 days Test the cytotoxicity of BAY-293 against NSCLC and PDAC cell lines PMC8488304
BxPC3 5 µM 4 days Test the synergy of BAY-293 with 2-DG, showing synergistic effects. PMC9437170
AsPC1 5 µM 4 days Test the synergy of BAY-293 with 2-DG, showing synergistic effects. PMC9437170
MIA PaCa-2 5 µM 4 days Test the synergy of BAY-293 with 2-DG, showing synergistic effects. PMC9437170
RD cells 0.2 µM BAY-293 significantly reduced MYC expression in RD cells. PMC11754616
BH1522 cells 0.2 µM BAY-293 inhibited proliferation and suppressed MYC activity in BH1522 cells. PMC11754616
KCL-22-IMR cells 1.932 μM (alone), 1.732 μM (combined with imatinib) BAY-293 alone or in combination with imatinib showed similar inhibitory effects on the proliferation of KCL-22-IMR cells. PMC8654699
KCL-22 cells 0.4, 0.8, 1.2, 1.6, 2.0 μM 48 hours BAY-293 inhibited the proliferation of KCL-22 and KCL-22-IMR cells in a dose-dependent manner. PMC8654699
K1 cells 1 µM, 10 µM, 25 µM 24 hours To evaluate the effect of BAY-293 on thyroid cancer cell viability, results showed that BAY-293 significantly reduced cell viability in a concentration-dependent manner. PMC11942110
FTC-133 cells 1 µM, 10 µM, 25 µM 24 hours To evaluate the effect of BAY-293 on thyroid cancer cell viability, results showed that BAY-293 significantly reduced cell viability in a concentration-dependent manner. PMC11942110
8305C cells 1 µM, 10 µM, 25 µM 24 hours To evaluate the effect of BAY-293 on thyroid cancer cell viability, results showed that BAY-293 significantly reduced cell viability in a concentration-dependent manner. PMC11942110
MIA PaCa-2 2.5 μM 24 hours BAY-293 promoted phosphorylation of ERK and AKT in a dose-dependent manner and increased expression of cleaved PARP, suggesting potential apoptosis promotion via feedback regulation. PMC9525295
PANC-1 2.5 μM 72 hours BAY-293 inhibited ERK phosphorylation, and a rebound in protein expression and phosphorylation levels was observed at 48 h (pERK) and 72 h (pAKT). PMC9525295
BH1406 NSCLC cells 1.12 µM 4 days BAY-293 significantly inhibited the viability of BH1406 cells with an IC50 value of 1.12 µM. PMC11632420
BH1406 NSCLC cells 0.5 µM 72 hours BAY-293 treatment significantly reduced the expression levels of SOS1 and MYC. PMC11632420
HT22 cells 2 μM 24 hours After inhibiting SOS1, the expression level of FBL was significantly reduced, indicating that BAY-293 regulates FBL expression by inhibiting SOS1, thereby reducing the inflammatory response. PMC11018134

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD/SCID mice BCR-ABL-independent imatinib resistance model Intraperitoneal injection 20 mg/kg Once daily for 7 days BAY-293 prolonged survival in a mouse model of BCR-ABL-independent resistance compared with saline or imatinib, showing significant efficacy. PMC8654699
BALB/c nude mice ATC orthotopic model Intraperitoneal injection 10 mg/kg, 50 mg/kg 2 weeks To evaluate the antitumor effect of BAY-293 in an ATC orthotopic model, results showed that BAY-293 significantly improved pathological features and reduced tumor growth. PMC11942110

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.23mL

0.45mL

0.22mL

11.15mL

2.23mL

1.11mL

22.29mL

4.46mL

2.23mL

References

 

Historical Records

Categories